TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35302455

Group type: EXPERIMENTAL
Intervention: Taboo group (interactive gaming, education-based strategy)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Storytelling group (education-based strategy using non-fictional and fictional case scenarios)
Number of subjects: 26
Study: 32869592

Group type: EXPERIMENTAL
Intervention: Acupoint injection of mouse nerve growth factor (mNGF) at various acupoints (0.3-0.5 mL, total 18 µg/2 mL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intramuscular injection of mouse nerve growth factor (mNGF) (18 µg/2 mL)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both interventions (Acupoint and Intramuscular)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Acupoint injection of mouse nerve growth factor (mNGF)
Number of subjects: 63
Study: 32200649

Group type: EXPERIMENTAL
Intervention: RSE-MA (10 m maximal acceleration, 2.12 m.s‐2)
Number of subjects: 16
Study: 32340650

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium Selenite (SS) addition (0.3 mg Se/kg DM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coated Sodium Selenite (CSS) addition (0.1, 0.2 and 0.3 mg Se/kg DM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medium Coated Sodium Selenite (MCSS) addition (0.2 mg Se/kg DM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High Coated Sodium Selenite (HCSS) addition (0.3 mg Se/kg DM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium Selenite (SS) or Coated Sodium Selenite (CSS) addition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium Selenite (SS), Medium Coated Sodium Selenite (MCSS) and High Coated Sodium Selenite (HCSS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High Coated Sodium Selenite (HCSS) addition
Number of subjects: 60
Study: 34228834

Group type: EXPERIMENTAL
Intervention: Running-related injuries (RRIs)
Number of subjects: 1929
Study: 36375565

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (NSPT) including oral hygiene instructions, scaling and root planing; and 0.05% Chlorhexidine mouthrinse
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group treatment including oral hygiene instructions, supragingival removal of plaque and calculus and 0.05% Chlorhexidine mouthrinse
Number of subjects: 40
Study: 34085475

Group type: EXPERIMENTAL
Intervention: Auricular point sticking therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham-auricular point therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 92
Study: 32169479

Group type: COMPARATOR
Intervention: Coffee (group C)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Tea (group T)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Tap water (group N)
Number of subjects: 3
Study: 35671228

Group type: COMPARATOR
Intervention: 25% HP for 45 minutes (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 5% PN for 45 minutes (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5% PN and 25% HP for 45 minutes (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3% PN in a 40% HP gel for 45 minutes (Group D)
Number of subjects: 90
Study: 32138625

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 2328

Group type: COMPARATOR
Intervention: Open Abdominal Aneurysm Repair (OAAR)
Number of subjects: 2328
Study: 34260092

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard patient education
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 33395931

Group type: EXPERIMENTAL
Intervention: Fresh source-separated human urine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stored source-separated human urine (after 30 days)
Number of subjects: 0
Study: 32726727

Group type: EXPERIMENTAL
Intervention: Evidence-based health education program
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine postpartum home visits (Control)
Number of subjects: 108
Study: 35272093

Group type: EXPERIMENTAL
Intervention: Early gestational diabetes mellitus screening at 14 to 20 weeks of gestation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Gestational diabetes mellitus diagnosed with routine screening at 24 to 28 weeks of gestation
Number of subjects: 119
Study: 34839804

Group type: EXPERIMENTAL
Intervention: High-threat video
Number of subjects: 207

Group type: COMPARATOR
Intervention: Low-threat video
Number of subjects: 207
Study: 35913665

Group type: EXPERIMENTAL
Intervention: Studied examples of deliberate reflection and explained the procedure to a fictitious peer on video
Number of subjects: 56

Group type: COMPARATOR
Intervention: Solved cases without reflection (control)
Number of subjects: 56
Study: 32772451

Group type: EXPERIMENTAL
Intervention: Reminder prompt to seek further medical attention
Number of subjects: 266

Group type: COMPARATOR
Intervention: No reminder prompt (control group)
Number of subjects: 266
Study: 32449942

Group type: EXPERIMENTAL
Intervention: Prazosin 16 mg/d, T.I.D.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35984033

Group type: EXPERIMENTAL
Intervention: Bone wax application
Number of subjects: 152
Study: 34125586

Group type: EXPERIMENTAL
Intervention: 2,000-word consent form
Number of subjects: 240

Group type: COMPARATOR
Intervention: 6,000-word consent form (control)
Number of subjects: 240
Study: 32212983

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg orally once daily
Number of subjects: 417

Group type: COMPARATOR
Intervention: Coenzyme A 400 mg orally once daily
Number of subjects: 417
Study: 33839766

Group type: EXPERIMENTAL
Intervention: Activity tracker intervention (Polar Loop 2) worn daily for 12 months
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (no activity tracker)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Activity tracker intervention (Polar Loop 2)
Number of subjects: 231
Study: 35254948

Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Number of subjects: 1949

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 1949

Group type: EXPERIMENTAL
Intervention: Lemborexant (both doses)
Number of subjects: 1949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1949
Study: 34029163

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (QHCl) 10 µmol/kg, intragastrically (IG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Denatonium benzoate (DB) 1 µmol/kg, intragastrically (IG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, intragastrically (IG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Denatonium benzoate (DB) 1 µmol/kg, intraduodenally (ID)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (QHCl) 10 µmol/kg, intraduodenally (ID)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, intraduodenally (ID)
Number of subjects: 14
Study: 32170552

Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 623

Group type: COMPARATOR
Intervention: LSG
Number of subjects: 623
Study: 36270271

Group type: EXPERIMENTAL
Intervention: Ultrasound guided axillary vein access (USAA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional venous access techniques
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inexperienced USAA implanters
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Experienced USAA implanter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: USAA
Number of subjects: 100
Study: 32663066

Group type: EXPERIMENTAL
Intervention: Digitally-enabled rehabilitation using eight digital devices (virtual reality videogames, activity monitors, handheld computer devices) for 6 months.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Physiotherapy contact every 1-2 weeks using a health coaching approach.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Support for device use categorized into initial set-up and instruction (27%), education and training (31%), maintenance (23%), and trouble-shooting (19%).
Number of subjects: 144
Study: 35962959

Group type: EXPERIMENTAL
Intervention: Language style matching (LSM)
Number of subjects: 25
Study: 34382947

Group type: EXPERIMENTAL
Intervention: AXA1125 24 g
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: AXA1957 20.3 g
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 32469946

Group type: EXPERIMENTAL
Intervention: Multi-joint training (MJ)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single-joint training (SJ)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 53
Study: 36273334

Group type: EXPERIMENTAL
Intervention: High frequency stimulation on bilateral hemisphere (5 Hz rTMS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation on affected hemisphere and low frequency stimulation on unaffected hemisphere (5 Hz rTMS on unaffected, 1 Hz rTMS on affected)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bilateral high frequency group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-low group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 45
Study: 33581097

Group type: EXPERIMENTAL
Intervention: Medical therapy for PH, primarily phosphodiesterase‐5 inhibitors
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Medical therapy for PH
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Medical therapy for PH in severe PH‐COPD
Number of subjects: 375

Group type: COMPARATOR
Intervention: PH‐COPD
Number of subjects: 375
Study: 32836188

Group type: EXPERIMENTAL
Intervention: 30% FiO2
Number of subjects: 252

Group type: COMPARATOR
Intervention: 80% FiO2
Number of subjects: 252
Study: 33858462

Group type: EXPERIMENTAL
Intervention: SCC1 (high intensity approach)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: SCC2 (low intensity approach)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Combined intervention groups
Number of subjects: 389

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: SCC1 (high intensity approach) among those trying to conceive
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: SCC2 (low intensity approach) among those trying to conceive
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Combined intervention arms among those trying to conceive
Number of subjects: 389

Group type: COMPARATOR
Intervention: Usual care among those trying to conceive
Number of subjects: 389
Study: 33029668

Group type: EXPERIMENTAL
Intervention: Culprit vessel only percutaneous coronary intervention (CO-PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate multivessel PCI (MV-PCI)
Number of subjects: 0
Study: 34787046

Group type: EXPERIMENTAL
Intervention: Active rTMS (5 Hz) applied over the left dorsolateral prefrontal cortex (DLPFC) for two weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rTMS for two weeks
Number of subjects: 60
Study: 34535716

Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: THP-1 cells
Number of subjects: 54
Study: 34574482

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 155
Study: 33209019

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (10 g, two times per day for 14 days)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 378
Study: 35445748

Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine (0.03 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine (0.03 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral transmucosal buprenorphine (0.03 mg/kg)
Number of subjects: 5
Study: 33984807

Group type: EXPERIMENTAL
Intervention: Active Attention Bias Modification (ABM)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo Attention Bias Modification (ABM)
Number of subjects: 301
Study: 32691499

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33806529

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg every night for six weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 35472193

Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (32 international units)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Number of subjects: 160
Study: 33499711

Group type: EXPERIMENTAL
Intervention: Exercise (15 minutes) before vaccination
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 57
Study: 35641151

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 0
Study: 32553118

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus berzosertib (210 mg/m2 on day 2 and day 9 of a 21-day cycle)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m2 on day 1 and day 8 of a 21-day cycle)
Number of subjects: 70
Study: 35076933

Group type: EXPERIMENTAL
Intervention: PSA screening at age 45
Number of subjects: 46642

Group type: COMPARATOR
Intervention: Digital rectal examination (DRE) with delayed PSA screening at age 50
Number of subjects: 46642
Study: 32050792

Group type: EXPERIMENTAL
Intervention: Drug therapy combined with psychological intervention (Cognitive behavioral therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Drug therapy only (Control group)
Number of subjects: 60
Study: 34294416

Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa plus chemotherapy (carboplatin and gemcitabine)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 71
Study: 35880079

Group type: EXPERIMENTAL
Intervention: S.boulardii monotherapy for 2 weeks followed by bismuth quadruple therapy if H. pylori positive after 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment for 6 weeks followed by bismuth quadruple therapy if H. pylori positive
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total treatment effect of S.boulardii and bismuth quadruple therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of S.boulardii
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 100
Study: 33358415

Group type: EXPERIMENTAL
Intervention: Nine stair climbing test (9SCT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chest expansion parameters
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Functional capacity (6MWT, 10mWT)
Number of subjects: 18
Study: 35694706

Group type: EXPERIMENTAL
Intervention: DCE‐MRI
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional MRI (Control)
Number of subjects: 124
Study: 32593555

Group type: EXPERIMENTAL
Intervention: Brief oral information and a leaflet on advanced directives (AD) provided by General Practitioners (GPs)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group received brief information about the study's purpose
Number of subjects: 332
Study: 32409324

Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 92

Group type: COMPARATOR
Intervention: CYC
Number of subjects: 92
Study: 35402445

Group type: EXPERIMENTAL
Intervention: CSF‐aspiration group (Group A) received spinal anesthesia with 10 mg of hyperbaric 0.5% bupivacaine with aspiration of 0.2 ml of CSF.
Number of subjects: 60

Group type: COMPARATOR
Intervention: No‐CSF‐aspiration group (Group B) received only 10 mg of 0.5% hyperbaric bupivacaine.
Number of subjects: 60
Study: 32390454

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 73

Group type: COMPARATOR
Intervention: non-efavirenz regimens or no antiretroviral therapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: tenofovir diphosphate (TFVdp)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: tenofovir
Number of subjects: 73
Study: 37430016

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 68
Study: 34495173

Group type: EXPERIMENTAL
Intervention: Stratification by Degree of Clinical Severity and Abandonment Risk of Tuberculosis Treatment (SRTB)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 432
Study: 32267646

Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard ALND without ARM)
Number of subjects: 0
Study: 35842610

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg) combined with 30 mL of 0.33% ropivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dexmedetomidine (0.5 μg/kg) combined with 20 mL of 0.5% ropivacaine
Number of subjects: 70
Study: 32622816

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Thought Field Therapy (TFT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) followed by Thought Field Therapy (TFT)
Number of subjects: 31
Study: 32144833

Group type: EXPERIMENTAL
Intervention: Resveratrol 1,000 mg per day for 8 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (methylcellulose)
Number of subjects: 76
Study: 33749362

Group type: EXPERIMENTAL
Intervention: Childcare PhysicaL ActivitY (PLAY) policy implemented by Early Childhood Educators for 8 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Program evaluation surveys and interviews conducted post-intervention
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Thematic analysis of interviews
Number of subjects: 21
Study: 34554634

Group type: EXPERIMENTAL
Intervention: PURE EP™ system (PURE)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional systems
Number of subjects: 51
Study: 32318288

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Homeostasis Evaluation Model (HOMA-IR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Physical activity analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST) analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Multiple linear regression for waist circumference (WC) and HOMA-IR
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HOMA-IR and percentage of lipids ingested
Number of subjects: 64
Study: 33825827

Group type: EXPERIMENTAL
Intervention: SlowMo plus usual care
Number of subjects: 361

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 361
Study: 32948442

Group type: EXPERIMENTAL
Intervention: Fellowship-trained chest radiologists
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Non-chest fellowship-trained radiologists
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fifth-year radiology residents
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall agreement with PCR-confirmed COVID status
Number of subjects: 70
Study: 36006657

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel®)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omentopexy
Number of subjects: 90

Group type: COMPARATOR
Intervention: No SLR (Control Group)
Number of subjects: 90
Study: 33567041

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 30

Group type: COMPARATOR
Intervention: Selective laser trabeculoplasty
Number of subjects: 30
Study: 32452356

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 6 months
Number of subjects: 3127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3127
Study: 35954905

Group type: EXPERIMENTAL
Intervention: dCBT-i (sleep intervention group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional education (control group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 97
Study: 33607312

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) 0.3 mg/kg administered intravenously on day 1 of a 42-day cycle for two cycles.
Number of subjects: 444

Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m2 administered intravenously on days 1 to 5 of a 21-day cycle.
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T)
Number of subjects: 444
Study: 33930787

Group type: COMPARATOR
Intervention: RDA diet (0.8 g/kg body weight/d)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 2RDA diet (2.0 g/kg body weight/d)
Number of subjects: 29
Study: 32036958

Group type: EXPERIMENTAL
Intervention: Feed restriction for 0, 4, 6, or 8 hours per day
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Feed restriction for 4 to 8 hours
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Feed restriction for 6 or more hours
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Feed restriction (length not specified)
Number of subjects: 2
Study: 35444030

Group type: EXPERIMENTAL
Intervention: Pictorial HWLs on tobacco packages
Number of subjects: 276

Group type: COMPARATOR
Intervention: Text only on tobacco package
Number of subjects: 276
Study: 34769863

Group type: EXPERIMENTAL
Intervention: Oral function training program
Number of subjects: 131

Group type: COMPARATOR
Intervention: Physical function training
Number of subjects: 131
Study: 32729919

Group type: EXPERIMENTAL
Intervention: Algorithm for determining medication count
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Clinical IHC by the reference standard
Number of subjects: 319

Group type: COMPARATOR
Intervention: Algorithm IHC false positives
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: IHC with contributing conditions
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Combined false-positive or IHC with contributing conditions
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Congestive heart failure as a contributing condition
Number of subjects: 319
Study: 36235654

Group type: EXPERIMENTAL
Intervention: Immediate intervention (Taste Education)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Delayed intervention (Control)
Number of subjects: 81
Study: 33529783

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) tranexamic acid (TXA) - two 1-g boluses, one prior to tourniquet inflation and one prior to wound closure
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) tranexamic acid (TXA)
Number of subjects: 110